Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Buys 20,000 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc bought 20,000 shares of the business’s stock in a transaction on Monday, November 9th. The shares were acquired at an average price of $8.24 per share, for a total transaction of $164,800.00. Following the completion of the purchase, the director owned 5,234,578 shares in the company, valued at approximately $43,132,922.72. The trade was a 0.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 10th, Orbimed Advisors Llc purchased 22,700 shares of Electra Therapeutics stock. The stock was acquired at an average price of $8.45 per share, with a total value of $191,815.00.
• On Friday, November 6th, Orbimed Advisors Llc purchased 49,416 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.85 per share, for a total transaction of $387,915.60.
• On Thursday, November 5th, Orbimed Advisors Llc acquired 156,091 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.31 per share, for a total transaction of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The stock was acquired at an average price of $7.53 per share, with a total value of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The stock was acquired at an average price of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Performance

ETRA traded down $0.23 during midday trading on Tuesday, hitting $7.99. 298,185 shares of the company traded hands, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a 52 week low of $6.86 and a 52 week high of $15.50.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ETRA. JPMorgan Chase & Co. assumed coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price objective on the stock. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. HC Wainwright assumed coverage on shares of Electra Therapeutics in a research note on Monday, October 26th. They set a “buy” rating and a $30.00 target price for the company. Zacks Research raised Electra Therapeutics to a “hold” rating in a report on Wednesday, October 14th. Finally, Cantor Fitzgerald initiated coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Electra Therapeutics has an average rating of “Buy” and a consensus price target of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.